September 3, 2013

Menomune® Is the First Quadrivalent Meningococcal Vaccine Prequalified by the WHO

Prequalification Makes the Vaccine Eligible for Purchase by United Nations Agencies

 

Menomune® Is the First Quadrivalent Meningococcal Vaccine Prequalified by the WHO
Prequalification Makes the Vaccine Eligible for Purchase by United Nations Agencies

Lyon, France – September 3, 2013 – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that one of its quadrivalent vaccines to prevent invasive meningococcal disease has been prequalified by the World Health Organization (WHO). The prequalification procedure accepts Menomune® vaccine for purchase by United Nations Agencies. The UNICEF supply division has been notified of Menomune vaccine’s acceptance by the WHO.